| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The compound targets inflammatory pathways and oxidative stress mechanisms. It can scavenge reactive oxygen species (ROS), regulate inflammatory pathways, and protect liver cells from toxin-induced injury.
|
|---|---|
| ln Vitro |
In vitro, Methylnissolin-3-O-glucoside demonstrates antioxidant activity by scavenging ROS. It also exhibits anti-inflammatory effects by modulating inflammatory cytokine production and hepatoprotective activity by protecting liver cells from injury.
|
| ln Vivo |
In vivo, this compound has been studied for its hepatoprotective effects in models of chemically induced liver injury. It reduces markers of liver damage and oxidative stress.
|
| Enzyme Assay |
Antioxidant activity is assessed using cell-free assays such as DPPH or ABTS radical scavenging assays. The compound is incubated with the radical solution, and the decrease in absorbance is measured spectrophotometrically.
|
| Cell Assay |
Hepatocytes or other cell lines are cultured and exposed to toxins (e.g., CCl4 or H2O2) in the presence of Methylnissolin-3-O-glucoside. Cell viability, ROS levels, and inflammatory cytokine production are measured.
|
| Animal Protocol |
Carbon tetrachloride-induced hepatotoxicity models in rodents are used to evaluate hepatoprotective effects. The compound is administered orally or intraperitoneally, and liver enzyme levels, oxidative stress markers, and histopathology are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not extensively characterized. As a glycoside, it is expected to undergo deglycosylation and hepatic metabolism. Oral bioavailability may be limited.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. Pterocarpan glycosides are generally considered to have a low toxicity profile. No significant adverse effects have been reported at research doses.
|
| References | |
| Additional Infomation |
Methylnissolin-3-O-glucoside is a research compound with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of antioxidant, anti-inflammatory, and hepatoprotective activities.
|
| Molecular Formula |
C23H26O10
|
|---|---|
| Molecular Weight |
462.4465
|
| Exact Mass |
462.153
|
| CAS # |
94367-42-7
|
| PubChem CID |
101679160
|
| Appearance |
White to off-white solid
|
| Density |
1.456±0.06 g/cm3 (20 °C, 760 mmHg)
|
| Boiling Point |
646.3±55.0 °C (760 mmHg)
|
| LogP |
0.492
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
665
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O(C1C(OC)=CC=C2C=1O[C@H]1C3C=CC(=CC=3OC[C@H]12)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C
|
| InChi Key |
PCIXSTFFMHVOMF-PBGSHFJYSA-N
|
| InChi Code |
InChI=1S/C23H26O10/c1-28-14-6-5-11-13-9-30-15-7-10(3-4-12(15)20(13)33-21(11)22(14)29-2)31-23-19(27)18(26)17(25)16(8-24)32-23/h3-7,13,16-20,23-27H,8-9H2,1-2H3/t13-,16+,17+,18-,19+,20-,23+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[[(6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromen-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~216.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1624 mL | 10.8120 mL | 21.6240 mL | |
| 5 mM | 0.4325 mL | 2.1624 mL | 4.3248 mL | |
| 10 mM | 0.2162 mL | 1.0812 mL | 2.1624 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
